T-DM1 did not exhibit a significant therapeutic effect in patients with HER2-positive NSCLC, contrary to the conclusions drawn from cellular and animal studies and in contrast to gastric cancer, which showed similar results. This evidence concerns the gene ERBB2 and gastric cancer.